Coya Therapeutics (NASDAQ:COYA) and Pluri (NASDAQ:PLUR) Head to Head Analysis

Coya Therapeutics (NASDAQ:COYA) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings for Coya Therapeutics and Pluri, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1	0	6	0	2.71
Pluri	1	0	0	0	1.00

Coya Therapeutics presently has a consensus target price of $15.33, suggesting a potential upside of 324.75%. Given Coya Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Coya Therapeutics is more favorable than Pluri.

Profitability

This table compares Coya Therapeutics and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Pluri	-2,344.59%	N/A	-82.71%

Earnings and Valuation

This table compares Coya Therapeutics and Pluri”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95 million	10.65	-$21.23 million	($1.07)	-3.37
Pluri	$1.02 million	15.33	-$23.82 million	($2.45)	-0.51

Coya Therapeutics has higher revenue and earnings than Pluri. Coya Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Coya Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Insider & Institutional Ownership

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Coya Therapeutics beats Pluri on 9 of the 14 factors compared between the two stocks.

About Coya Therapeutics

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.